“One day, I wish everyone dealing with a rare condition will have access to a treatment. I really hope you will enjoy reading these memories… and learn more about this Global Crusade.” – Abbey Meyers
In her new memoir, Orphan Drugs: A… Read More
The following Letter to the Editor by NORD President & CEO Peter L. Saltonstall appeared in the Wall Street Journal (January 2, 2016). You read the letter online on the Wall Street Journal website.
Wall Street Journal
January 2, 2016
Dr. Makary… Read More
The U.S. Food and Drug Administration announced today it approved 21 new orphan drugs to treat rare diseases in 2015, nearly half (47 percent) of all novel new drugs approved for the year. This is the second consecutive year… Read More
Washington, D.C., July 30, 2015 – The National Organization for Rare Disorders (NORD) has filed an amicus brief in the D.C. Circuit of the U.S. Court of Appeals, stating that a recent Food and Drug Administration (FDA) decision has the potential to impede the development of new treatments to… Read More
Today, the National Organization for Rare Disorders (NORD), Biotechnology Industry Organization (BIO), and Ernst & Young released “Impact of the Orphan Drug Tax Credit on Treatments for Rare Diseases,” a new white paper examining the role of the Orphan Drug Tax Credit (ODTC) on rare disease drug discovery. Patients share… Read More
